Future Fields vs athenahealth

Side-by-side comparison of AI visibility scores, market position, and capabilities

athenahealth leads in AI visibility (95 vs 26)
Future Fields logo

Future Fields

EmergingHealthcare

General

Precision fermentation biotech producing animal-free growth factors for cultivated meat and cell therapy; Drosophila expression system enabling lower-cost recombinant protein production.

AI VisibilityBeta
Overall Score
D26
Category Rank
#533 of 1158
AI Consensus
79%
Trend
up
Per Platform
ChatGPT
22
Perplexity
23
Gemini
25

About

Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.\n\nFuture Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.\n\nIn 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.

Full profile
athenahealth logo

athenahealth

LeaderHealthcare

Cloud EHR

$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025

AI VisibilityBeta
Overall Score
A95
Category Rank
#1 of 1
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
95
Gemini
91

About

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.

Full profile

AI Visibility Head-to-Head

26
Overall Score
95
#533
Category Rank
#1
79
AI Consensus
71
up
Trend
stable
22
ChatGPT
92
23
Perplexity
95
25
Gemini
91
29
Claude
99
20
Grok
86

Key Details

Category
General
Cloud EHR
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only athenahealth
Cloud EHR

Integrations

Only athenahealth

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.